1.05% 0.0488

Amneal Pharmaceuticals Inc (AMRX)

Überblick Nachrichten Preisverlauf Optionskette Forum Prognose

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile

Amneal Pharmaceuticals Inc

Healthcare (1155)

908-947-3120

400 Crossing Boulevard, 3rd Floor, Bridgewater

@amnealpharma

Nächster Verdiensttermin

Neueste SEC-Einreichungen

AMRX's Discussions on Twitter

Vergleichen Sie AMRX mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
AMRX Amneal Pharmaceuticals Inc	7.18	2.25B	2.68B	-184.45M	229.23M	-0.6805
ZTS Zoetis Inc	149.31	66.56B	9.26B	2.49B	2.30B	5.47
HLN Haleon Plc Adr	10.44	45.61B	14.35B	1.85B	0	0.4023
TAK Takeda Pharmaceutical Co Adr	15.26	45.01B	30.25B	1.37B	5.08B	0.4257
TEVA Teva Pharmaceutical Industries Ltd Adr	13.89	15.25B	16.54B	-1.64B	749.00M	-1.45
UTHR United Therapeutics Corp	288.91	12.79B	2.76B	1.11B	898.10M	22.77

Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-02-24	Hochstufung	JP Morgan	Neutral → Overweight
2024-09-06	Hochstufung	JP Morgan	Underweight → Neutral
2021-04-07	Fortgesetzt	RBC Capital Mkts	Sector Perform
2021-03-08	Hochstufung	Goldman	Sell → Buy
2020-12-14	Hochstufung	Barclays	Equal Weight → Overweight
2020-12-14	Hochstufung	Guggenheim	Neutral → Buy
2020-07-27	Eingeleitet	Goldman	Sell
2020-05-12	Hochstufung	Guggenheim	Sell → Neutral
2019-12-12	Herabstufung	Raymond James	Outperform → Mkt Perform
2019-11-12	Herabstufung	JP Morgan	Neutral → Underweight
2019-11-07	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2019-07-22	Hochstufung	SVB Leerink	Mkt Perform → Outperform
2019-07-11	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2019-07-08	Hochstufung	Piper Jaffray	Neutral → Overweight
2019-06-11	Eingeleitet	Barclays	Equal Weight
2019-05-21	Hochstufung	Raymond James	Mkt Perform → Strong Buy
2019-03-20	Eingeleitet	SunTrust	Buy
2019-03-08	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2018-12-14	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2018-10-16	Herabstufung	SunTrust	Buy → Hold
2018-08-13	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2018-07-23	Eingeleitet	Morgan Stanley	Overweight
2018-06-22	Eingeleitet	B. Riley FBR, Inc.	Buy

Alle ansehen

Amneal Pharmaceuticals Inc Aktie (AMRX) Neueste Nachrichten

Finanzdaten der Amneal Pharmaceuticals Inc-Aktie (AMRX)

Amneal Pharmaceuticals Inc (AMRX)

Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile

Vergleichen Sie AMRX mit anderen Aktien

Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades

Amneal Pharmaceuticals Inc Aktie (AMRX) Neueste Nachrichten

Amneal Pharmaceutical LLC Issues a Nationwide Recall of Ropivacaine Hydrochloride Injection, USP 500mg/100mL, Due to the Potential Presence of Particulate Matter - usrecallnews.com

Even though Amneal Pharmaceuticals (NASDAQ:AMRX) has lost US$78m market cap in last 7 days, shareholders are still up 125% over 5 years - Yahoo Finance

Is Amneal Pharmaceuticals, Inc. (AMRX) the Best Pharma Stock to Buy for Long Term Growth? - Insider Monkey

Lobbying Update: $60,000 of AMNEAL PHARMACEUTICALS INC. lobbying was just disclosed - Nasdaq

10 Best Pharma Stocks to Buy for Long Term Growth - Insider Monkey

Amneal donates $1.5M this Parkinson’s Awareness Month - NJBIZ

NY AG reaches $270M multistate opioid settlement with Amneal Pharmaceuticals - Class Action Lawsuits

Amneal Donates $1.5 Million to Support Patients During Parkinson’s Awareness Month - BioSpace

Amneal's $1.5M Donation Makes Parkinson's Medications More Accessible for Thousands - Stock Titan

Amneal to Report First Quarter 2025 Results on May 2, 2025 - Bluefield Daily Telegraph

Amneal Launches Boruzu for Multiple Myeloma and Mantle Cell Lymphoma - Clinical Oncology News

Amneal Earnings Preview: Key Updates Coming May 2 in Q1 2025 Report - Stock Titan

Amneal’s CREXONT improves sleep in Parkinson’s patients By Investing.com - Investing.com South Africa

Amneal's Combination Drug Shows Improved Sleep Quality In Parkinson's Disease Patients - Benzinga

Amneal Announces New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Parkinson’s Disease - BioSpace

Amneal Announces New Data From Phase 3 Study - MarketScreener

Amneal’s CREXONT improves sleep in Parkinson’s patients - Investing.com

Breakthrough: New Parkinson's Drug Shows Major Sleep Quality Gains in Phase 3 Trial - Stock Titan

Amneal Boruzu Subcutaneous Formulation Launch - Specialty Pharmacy Continuum

Amneal Pharmaceuticals (AMRX) Expands Coverage for Parkinson's D - GuruFocus

Amneal Announces Expanded Coverage for CREXONT® (Carbidopa and Levodopa) to Enhance Access for Parkinson’s Disease Patients in the U.S. - BioSpace

Amneal gets expanded coverage for Parkinson’s disease drug - Seeking Alpha

Amneal Announces Expanded Coverage For Crexont® To Enhance Access For Parkinson'S Disease Patients In The U.S. - marketscreener.com

Breakthrough: Amneal's Parkinson's Drug CREXONT Secures Game-Changing Insurance Coverage - Stock Titan

Amneal and Shilpa introduce Boruzu in US for cancer treatment - Yahoo Finance

Amneal Launches BORUZU™, First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma - The Joplin Globe

Amneal Launches BORUZU , First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma - Business Wire

Groundbreaking Cancer Treatment: First Ready-Made Bortezomib Injection Hits Market - Stock Titan

Amneal Achieves Third U.S. Biosimilar Approval with FYLNETRA™ (pegfilgrastim-pbbk) - Business Wire

Myasthenia Gravis Treatment Market Size, Growth Analysis 2031 - openPR

Insiders At Amneal Pharmaceuticals Sold US$48m In Stock, Alluding To Potential Weakness - simplywall.st

Amneal Digs Deeper Into GLP-1 Aspirations Following Metsera’s IPO - insights.citeline.com

Amneal Pharmaceuticals: Shares Still Feel Significantly Undervalued (NASDAQ:AMRX) - Seeking Alpha

Amneal Pharmaceuticals (AMRX) Stock Soars 45% on Success of New Parkinson’s Treatment - Markets Insider

Amneal Pharmaceuticals’ SWOT analysis: generic drug maker’s stock poised for growth By Investing.com - Investing.com South Africa

Amneal Pharmaceuticals’ SWOT analysis: generic drug maker’s stock poised for growth - Investing.com

Amneal at Barclays Healthcare Conference: Growth and Innovation Insights By Investing.com - Investing.com UK

Amneal to Participate at Upcoming March 2025 Investor Conference - BioSpace

Amneal to Participate at Upcoming Investor Conference - WICZ

Amneal Pharmaceuticals EVP Jason Daly sells $792,159 in stock By Investing.com - Investing.com Australia

Amneal Pharmaceuticals CFO Tasos Konidaris sells $891,000 in stock By Investing.com - Investing.com India

Amneal Pharmaceuticals EVP Andrew Boyer sells $1.1 million in stock By Investing.com - Investing.com Canada

Insider Exodus: Amneal Pharmaceuticals Executives and Directors Offload Massive Stock Holdings - TipRanks

Amneal Pharmaceuticals EVP Jason Daly sells $792,159 in stock - Investing.com

Teva denied stay in Amneal patent dispute as it appeals to Supreme Court - MLex

Amneal Pharmaceuticals EVP Andrew Boyer sells $1.1 million in stock - Investing.com

Amneal Pharmaceuticals CFO Tasos Konidaris sells $891,000 in stock - Investing.com

Amneal Pharmaceuticals director Alva Emily Peterson sells $712,000 in stock - Investing.com

Amneal Pharmaceuticals Executives and Director Sell Shares - TradingView

Finanzdaten der Amneal Pharmaceuticals Inc-Aktie (AMRX)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie AMRX